SOUTH SAN FRANCISCO, Calif.,
Sept. 24, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Cantor Global Healthcare Conference in
New York City on Wednesday, October 3, 2018 at 1:05pm EDT.
The audio presentation will be webcast live and may be accessed
on the company's website under the investors section at
www.rigel.com, where a copy of the presentation materials will
be available for download. Please connect to Rigel's website
several minutes prior to the start of the live webcast to ensure
adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc., is a biotechnology company dedicated to
discovering, developing and providing novel small molecule drugs
that significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE™
(fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase
(SYK) inhibitor, for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. Rigel's current clinical programs include Phase
2 studies of fostamatinib in autoimmune hemolytic anemia and IgA
nephropathy. In addition, Rigel has product candidates in
development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris
Therapeutics.
Please see www.TAVALISSE.com for full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-cantor-global-healthcare-conference-300717138.html
SOURCE Rigel Pharmaceuticals, Inc.